Kinome siRNA survival screen results Acknowledgements Discovery and investigation of novel radiosensitising genes Gaganpreet Tiwana 1, Remko Prevo 1, Balam.

Slides:



Advertisements
Similar presentations
Supplementary Data shLuc sh   sh  179 shLuc sh   sh  179 Asyn Noco 2.1% 6.1% 2.4% 16.5%11.4%1.1% 5.9%3.9%2.5% 52.5%10.0%4.9%
Advertisements

Supplemental Figure 1 actin MocksiRNA1siRNA2Mock Li Fraumeni (087)5C tankyrase1 100
V Dissecting the cellular response to DNA breaks using functional genomics Ásta Björk Jónsdóttir, Paul Russell, Alessandro Esposito, Tamara Gruener, Ashok.
Development of Assays for Use in Patient Response Measurement in Phase 0 Trials Robert Kinders Ralph Parchment Pharmacodynamic Assay Development and Implementation.
Ahmed Group Lecture 6 Cell and Tissue Survival Assays Lecture 6.
Radiation Therapy (RT). What is cancer? Failure of the mechanisms that control growth and proliferation of the cells Uncontrolled (often rapid) growth.
Discussion Our current results suggest that it is possible to identify susceptibility regions using this methodology. The presented method takes advantage.
BIOLOGICAL EFFICIENCY OF A THERAPEUTIC PROTON BEAM: A STUDY OF HUMAN MELANOMA CELL LINE I. Petrović 1, A. Ristić-Fira 1, D. Todorović 1, L. Korićanac 1,
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
A National Science Foundation Engineering Research Center in the MSU College of Engineering Center for Biofilm Engineering Bias is defined as the systematic.
Analysis of the Full Ewing EWS/FLI Screen Ken Ross 10/22/10 The Broad Institute of MIT and Harvard.
TREATMENT PLANNING Modelling chemo-hadron therapy Lara Barazzuol | Valencia | 19 June 2009.
Lentiviral shRNA screen to test the validity of a gene signature of breast cancer stem cells using high throughput mammosphere assays Jenny Chang Lab.
The Center for Medical Genomics facilitates cutting-edge research with state-of-the-art genomic technologies for studying gene expression and genetics,
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
Training Module 3 – Version 1.1 For Internal Use Only ® Radiation Therapy 
Superiority of 160 kV vs 6 MV X- ray irradiation combined with heavy element radiosensitization By: Sara N. Lim, Anil K. Pradhan, Sultana N. Nahar, Rolf.
Background Western Blot Semi-Quantitative Analysis of Non-Canonical cAMP-Dependent Protein Expression Induced by PACAP Emily Jones with Yvonne Holighaus.
A Tumour Control Probability based approach to the development of Plan Acceptance Criteria for Planning Target Volume in Intensity Modulated Radiation.
Mathematical Modelling within Radiotherapy: The 5 R’s of Radiotherapy and the LQ model. Helen McAneney 1 and SFC O’Rourke 1,2 1 School Mathematics and.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
TLD POSTAL DOSE QUALITY AUDIT FOR 6MV AND 15MV PHOTON BEAMS IN RADIOTHERAPY CLINICAL PRACTICE Sonja Petkovska 1, Margarita Ginovska 2, Hristina Spasevska.
Karolina Kokurewicz Supervisors: Dino Jaroszynski, Giuseppe Schettino
UK Clinical Sarcoma Research. Changes in UK Appointment of Cancer Tsar Use of NICE to evaluate care pathways and technology/drugs Minimum datasets established.
Bioassay Optimization and Robustness Using Design of Experiments Methodology 2015 NBC, San Francisco June 8, 2015 Kevin Guo.
Transfection Optimisation Process Each new siRNA screen entering the TDI requires a full transfection optimisation process. For RNAi screens, establishing.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immune Response During Therapy With Cisplatin or Radiation.
The Effects of Small Field Dosimetry on the Biological Models Used In Evaluating IMRT Dose Distributions Gene Cardarelli,PhD, MPH.
Methods & Materials (continued)
Figure 5 ISOX and vorinostat partially restore splicing pattern in DM1 patient-derived fibroblasts. (A) ISOX and vorinostat partially rescue mis-splicing.
ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.
Introduction Conclusions
Significance Analysis of Microarrays (SAM)
Insert tables Insert figure
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.
A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation  Lily Mahapatra, Neal Andruska, Chengjian Mao,
The impact of the IGF-1 system of cancer cells on radiation response – An in vitro study  Senthiladipan Venkatachalam, Esther Mettler, Christian Fottner,
MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis  Motofumi.
Significance Analysis of Microarrays (SAM)
Supplemental Figure 1 Li Fraumeni (087) 5C tankyrase1 actin Mock
DNAPKcs is required for DNA repair in the presence of androgen.
Figure 2 Host immune responses, not the radiosensitivity
Implementing Genome-Driven Oncology
A B C E F D IC50 = 567 nM IC50 = 83 nM HAP1 WT HAP1 TOPK
Volume 24, Issue 8, Pages (August 2018)
AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer  Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,
Human RAD50 Deficiency in a Nijmegen Breakage Syndrome-like Disorder
A C D B Asynchronous nM Nocodazole 150 ► 100 ► 75 ►
The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and.
Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
Multiple Functions of the 37/67-kd Laminin Receptor Make It a Suitable Target for Novel Cancer Gene Therapy  Jonathan Scheiman, Jen-Chieh Tseng, Yun Zheng,
Oncogenic Ras-Induced Expression of Noxa and Beclin-1 Promotes Autophagic Cell Death and Limits Clonogenic Survival  Mohamed Elgendy, Clare Sheridan,
A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.
An siRNA screen identifies BER pathway members as sensitizers to temozolomide (TMZ) in pediatric GBM. A and B, SJG2 and KNS42 cells were transfected with.
ADAR Regulates RNA Editing, Transcript Stability, and Gene Expression
Volume 12, Issue 3, Pages (September 2003)
RSLs enable internal replicate and lineage dropout analyses
Volume 20, Issue 3, Pages (March 2013)
Volume 8, Issue 5, Pages (September 2014)
SYCE2 induces resistance to ionizing radiation and cisplatin in somatic cells. SYCE2 induces resistance to ionizing radiation and cisplatin in somatic.
Effect of siRNA transfection on colony formation by Renca cells.
Volume 26, Issue 10, Pages (October 2018)
PX-478 directly radiosensitizes tumor cells in vitro.
Effects of WDL on in vitro invasion and soft agar colony formation by LNCaP cells. Effects of WDL on in vitro invasion and soft agar colony formation by.
Radiosensitization by combined Wee1 and PARP inhibition.
High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.
siRNA screen validation.
Volume 26, Issue 9, Pages e5 (September 2019)
Presentation transcript:

Kinome siRNA survival screen results Acknowledgements Discovery and investigation of novel radiosensitising genes Gaganpreet Tiwana 1, Remko Prevo 1, Balam Budwal 1,Daniel Ebner 2, Alison Howarth 2, Kwun-Ye Chu 1, Lisa Durrant 1, Gillies McKenna 1, Geoffrey Higgins 1 1 Gray Institute for Radiation Oncology and Biology, Oxford, UK 2 Target Discovery Institute, Oxford, UK Introduction Radiotherapy treatment is a balance between tumour control and normal tissue complication probabilities Widening this treatment window can be achieved by modulating intrinsic radiosensitivity of tumour cells Key determinants of intrinsic radiosensitivity remain largely unknown Novel determinants of radiosensitivity can be identified through high- throughput siRNA screening employing a relevant radiation endpoint. Colony formation is the gold standard in assessing the replicative potential of a tumour cell following radiation treatment. ‘Aim of this study is to identify novel radiosensitising genes using high throughput clonogenic survival siRNA screens’ Experimental procedure Kinome and Druggable genome (Dharmacon ON-TARGETplus) siRNA library screens were conducted in HeLa cells quantifying colony formation following irradiation(IR) as an endpoint. The kinome and druggable libraries consisted of a combined total 128 plates (96- well), run in separate batches. 96-well experimental plates containing target siRNA were transfected on day 1 at a concentration of 20nM using DharmaFECT1 transfection reagent. 72hrs post transfection, cells were lifted and plated into two sets of quadruplicate repeat 96-well plates. Plates were left to adhere for 4hrs. Treatment plates were irradiated at 7 Gy using 6MV X-ray photons delivered by Varian Clinac iX Linear accelerator. Plates were incubated for 7-9 days and stained with crystal violet. Colonies were counted and Z-scores calculated. Figure 1 Schematic diagram of the screen procedure of one library plate. HeLa cells were transfected by reverse transfection on day 1 and on day 4 lifted in trypsin, transferred to a 96 deepwell plate, from which approximately 190 cells/well were transferred to the 0Gy plates and 1600 cells/well to the 7Gy plates. Colonies on the 96-well plates were stained with crystal violet stain and quantitated one week later. Colonies were counted using the GelCount colony counter (Oxford Optronix). X-Rays Staining 0 Gy 7 Gy Kinome siRNA library consisting of 709 genes was screened using the 96-well plate colony formation assay. The Z factor for the screen was Z scores were calculated to evaluate if target genes were radiosensitising ( Z score <0). Surviving fractions (SF) were first calculated by dividing the mean number of colonies following irradiation by the mean number of colonies in un-irradiated controls. SF of target genes were normalised to the average SF of non-targeting (NT) control siRNA wells (n=8) on each plate to take into account plate variations. Z score= (Normalised SF- Normalised median NT SF across all plates)/(Average deviation of NT SF across all plates) Known radiosensitising genes were identified in the screen, which included ATM, ATR, CHEK1 and DNA-PKcs (Figure 2A). Seven possible novel radiosensitising genes have been identified and are being investigated in 6-well colony formation assays using siRNA from a different vendor to confirm the absence of off-target effects. Genes A and B are shown as examples of genes providing tumour specific radiosensitisation in HeLa, PSN1 and SQ20B cell lines. (Figure 2B) PRKDC/ DNA-PKcs Gene B ATM ATR Gene A Figure 2 A. Z-score diagram of the Kinome library screen highlighting known radiosensitivity determinants that were identified as hits. The identification of ATM, ATR,CHEK1, PRKDC (DNA-PKcs) among the top genes whose depletion caused reduced radiosurvival is proof of principal for the screening assay. B. Tumour specific radiosensitisation caused by siRNA depletion of Gene A & B. 6-well colony formation assay carried out with 20nM target siRNA (Ambion ON-TARGETplus ) in HeLa, PSN1 and SQ20B cancer cell lines. A B HeLa PSN1 SQ20B We have successfully developed and implemented a high throughput 96-well colony formation screen to identify novel radiosensitising genes. The screen has identified seven possible novel radiosensitisers in the kinome siRNA library. The druggable siRNA library screen has been concluded, yielding a Z-factor of Validation of novel radiosensitising genes is underway. This screen setup will also be used to screen compound libraries to identify novel radiosensitising drugs. Conclusions Day 1 transfection Day 4 plating and irradiation 7-9 days incubation This work was supported by Medical Research Council, Cancer Research UK and NIHR biomedical research centre, Oxford. Contact :